SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.
$BBOT
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2026 | $23.00 | Buy | Stifel |
| 1/9/2026 | $24.00 | Outperform | Raymond James |
| 12/5/2025 | $20.00 | Overweight | Morgan Stanley |
| 9/17/2025 | $25.00 | Outperform | Leerink Partners |
| 9/15/2025 | $27.00 | Buy | H.C. Wainwright |
| 8/15/2025 | $21.00 | Overweight | Piper Sandler |
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO-10203, BBOT's selective RAS:PI3Kα breaker Preliminary clinical data from the BBO-11818 Phase 1 KONQUER-101 trial showed encouraging anti-tumor activities and differentiated safety, with additional data expected in the second half of 2026; interna
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520's differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT's intern
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company's participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. ET. Leerink Global Healthcare ConferencePresentation: Tuesday, March 10, 2026, at 10:00 a.m. ET. Live webcasts of the presentations will be accessible on the "Events" page of the BBOT website at h
Stifel initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $23.00
Raymond James initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $24.00
Morgan Stanley initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $20.00
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
10-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar